Westpac subsidiary BT Funds Management and Tal Life Insurance have foreshadowed applications to strike out the pleadings of a class action alleging superannuation customers were overcharged for insurance coverage.
The lead plaintiff and several group members in a class action against the Australian Football League on behalf of players who allegedly suffered brain injuries have “very strong” opposition to adding individual clubs, a court has heard.
A judge has dismissed the corporate regulator’s first-ever case over unfair insurance contracts terms, finding it was not unfair for an insurer to require customers to notify it if anything changed about their home or its contents.
Hells Angels has asked the High Court to reinstate an award of $78,000 for online marketplace Redbubble’s infringement of its trade marks, after the Full Court found it was owed just $100 in nominal damages.
Investors in an apartment development in Melbourne have brought a class action against the responsible managers for two managed investment schemes, alleging their funds were misused.
Google has criticised two competition class actions which piggyback on claims brought by Fornite developer Epic Games as “opportunistic”, but counsel for the class actions told a court the suits on behalf of more than 15 million group members were in the public interest.
A judge has set aside subpoenas in a class action against Mercedes-Benz over alleged emissions cheating seeking material to identify group members and clarify the composition of the class, finding they were not issued for a legitimate forensic purpose.
The AFL has scored a small victory in concussion litigation brought by players, winning an order temporarily halting a case by former Western Bulldogs player Liam Picken.
A client of EY has sued a former partner at the firm, accusing them of collecting $700,000 in secret payments as part of a tax loss scheme.
The Australian unit of drug giant Mylan has triumphed in a dispute with Australian Taxation Office, with a judge finding the ATO’s assessment for 2020 was “excessive” with respect to interest on loans to fund Mylan’s $1.2 billion acquisition of generic drug maker Alphapharm.